Biosimilars – Forecast – Oncology
In 2023, sales of branded MAb biologics in oncology exceeded $47 billion in the major pharmaceutical markets (United States, EU5, and Japan), and sales of biosimilars totaled approximately $5.5 billion. Throughout the 2023-2033 forecast period, increasing numbers of branded biologics will lose patent protection, and biosimilars will enter the market and erode both patient share and drug prices. We present our forecasts for key reference brands and their biosimilars by molecule and country / region.
Table of contents
- Biosimilars - Forecast - Oncology
- Oncology MAb Forecasts
- G-CSF Forecasts
- Market Forecast in the Major Pharmaceutical Markets
- Overarching Forecast Assumptions
- Drug-Specific Forecast Assumptions
- Avastin
- Cyramza
- Erbitux
- Herceptin
- Outlook for Herceptin IV
- Outlook for Herceptin SC
- First biosimilars of Herceptin IV in the major pharmaceutical markets
- First biosimilars of Herceptin SC in the major pharmaceutical markets
- Order of entry in the United States (Herceptin IV biosimilars)
- Order of entry in the United States (Herceptin SC biosimilars)
- Order of entry in the EU5 (Herceptin IV biosimilars)
- Order of entry in the EU5 (Herceptin SC biosimilars)
- Order of entry in Japan
- Forecast assumptions
- Market forecast: Herceptin
- Imfinzi
- Kadcyla
- Keytruda
- Opdivo
- Perjeta
- Rituxan / MabThera
- Outlook for Rituxan / MabThera
- First biosimilars of Rituxan in the major pharmaceutical markets
- Order of entry in the United States
- Order of entry in the EU5
- Order of entry in Japan
- Forecast assumptions
- Market forecast: Rituxan / MabThera: Oncology
- Market forecast for Rituxan / MabThera: immunology and oncology
- Tecentriq
- Vectibix
- Yervoy
- Neupogen / Gran
- Neulasta / G-Lasta
Related Market Assessment Reports
Report
Eosinophilic Esophagitis – Current Treatment – Treatment Algorithms: Claims Data Analysis – Eosinophilic Esophagitis (US)
Eosinophilic esophagitis (EoE) is a chronic allergic inflammatory condition of the esophagus, marked by an accumulation of eosinophils. This can lead to difficulty swallowing and potentially…
Report
Metabolic Dysfunction-Associated Steatohepatitis – Unmet Need – Unmet Need – Metabolic Dysfunction-Associated Steatohepatitis (US/EU)
Metabolic dysfunction-associated steatohepatitis (MASH), previously known as nonalcoholic steatohepatitis (NASH), has the potential to be a large and lucrative therapy market owing to the disease…
Report
Hepatocellular Carcinoma – Geographic Focus: China – Hepatocellular Carcinoma – China In-Depth (China)
The hepatocellular carcinoma therapy market in China is poised to experience significant growth, driven by an aging population and the high prevalence of hepatitis B and C infection. Angiogenesis…
